What is Mounjaro

Mounjaro (tirzepatide) is a prescription-only once-weekly injection that may be prescribed for weight management alongside a reduced-calorie diet and increased physical activity. It activates the GLP-1 and GIP receptors (hormones involved in appetite regulation), which can help some people feel fuller and reduce appetite.

In clinical studies in adults with obesity (or overweight with weight-related health conditions), average weight reduction with tirzepatide alongside lifestyle measures was around 15% to 22% over about 72 weeks, depending on dose. Individual results vary and weight loss is not the same for everyone.

Mounjaro is injected once a week, on the same day each week. Each pre-filled pen contains four fixed weekly doses, so one pen lasts four weeks. Dose changes (including dose increases) should only be made in line with the prescribed plan following clinical review.

Eligibility (subject to clinical assessment)

Mounjaro may be supplied to adults who:

• have a BMI of 30 kg/m² or above, or
• have a BMI of 27 kg/m² or above with at least one weight-related health condition (e.g. High blood pressure (hypertension), High cholesterol (dyslipidaemia), Obstructive sleep apnoea, Type 2 diabetes).

Supply is only available following an online consultation to check suitability, medical history and current medicines, and a clinician's approval.

Price and service

Pricing is shown upfront and includes the online/phone clinical assessment, the medication and delivery. There are no separate consultation or delivery fees.

Delivery and what's included

If approved, your medication is dispensed by a UK-registered pharmacy and delivered in validated temperature-controlled packaging designed to help maintain appropriate refrigerated conditions in transit. Your order includes needles and usage guidance; a sharps bin can be provided if needed.

Dosage

Mounjaro follows a gradual dosing schedule to help your body adjust and minimise potential side effects as you increase to an effective maintenance dose. Starting with the lowest dose and gradually increasing it every four weeks is advised. Please select the dosage as recommended in your personalised treatment plan. If you’re uncertain about the right dose, please contact our pharmacist at (pharmacy@medino.com) before ordering.

For individuals with a BMI over 50, we strongly recommend consulting with a doctor or specialist for a comprehensive treatment plan.

FAQs

How much weight can I lose with Mounjaro?

In clinical trials involving adults with obesity or overweight, participants lost an average of:

• Up to 15% of their body weight with the 5 mg dose.
• Around 20% of their body weight with the 10 mg dose.
• Up to 22.5% of their body weight with the 15 mg dose after 72 weeks of treatment.

How often do I use a Mounjaro pen?

Mounjaro is injected once a week on the same day each week, if possible. You can inject it at any time of day, with or without food, into your abdomen, thigh or upper arm. If you need to change your injection day, ensure there are at least 3 days (72 hours) between doses.

How should I store Mounjaro pens?

Unused Mounjaro pens should be stored in the refrigerator at 2°C to 8°C and kept in their original carton to protect them from light. Do not freeze the pen, and never use it if it has been frozen. Once in use, the UK Mounjaro KwikPen can be stored at temperatures below *0°C for up to 30 days, after which it should be discarded.

What should I do if I miss a Mounjaro injection?

If you miss a dose, take it as soon as possible within 4 days (96 hours) of your scheduled injection. If more than 4 days have passed, skip the missed dose and take your next injection on your usual day. Never take two doses within 3 days of each other to make up for a missed injection.

What is the difference between Mounjaro and Ozempic?

• Ozempic contains semaglutide, which works only on the GLP-1 receptor.
• In clinical studies, Mounjaro has generally demonstrated greater average weight loss than semaglutide, although the most suitable treatment depends on your medical history, treatment goals and your prescriber's recommendation.
• In the UK, Ozempic is licensed for type 2 diabetes, while Mounjaro is licensed for both type 2 diabetes and weight management in eligible adults.

Patient information leaflet

Our service does not include a prescription. Instead, your treatment is supplied under a legal framework known as a Patient Group Direction (PGD). The process follows these steps:

1. Complete a health questionnaire

Provide detailed information about your health, medical history, and previous weight management efforts.

2. Pharmacist review

A pharmacist will review your responses and may contact you by phone or video call if further information is required to support safe supply.

3. Private consultation

All interactions are confidential. This provides an opportunity to discuss any questions and ensure appropriate use of the treatment.

4. Identity verification

You may be asked to provide identification to confirm that you are the intended user. This is typically required for your first order only.

5. Supporting evidence

You may be asked to provide relevant information, such as confirmation of weight, height, or medical history, to support safe supply.

Your GP will be notified of your request and the outcome of the supply decision, whether the treatment is supplied or not, to support continuity of care.

Purchasing this medication does not guarantee supply. The decision to supply is made by the pharmacist based on the information provided. If supply is not appropriate, your order will be refunded.

Each dose contains 5mg of tirzepatide in 0.6 ml solution.

Other ingredients: Sodium phosphate dibasic heptahydrate, Sodium chloride, Concentrated hydrochloric acid, and sodium hydroxide (for pH adjustment), Water for injections

Each Mounjaro 5mg order from medino includes:

• 1 × Mounjaro pen
• 4 × Needles (not replaceable if faulty/damaged)
• 8 × Pre-injection wipes

1. Wash hands and clean the injection site (thigh, abdomen, or upper arm) with an alcohol wipe.
2. Attach a new needle to the pen and set the prescribed dose.
3. Insert the needle at a 90-degree angle, press and hold the dose button, and count to 5.
4. Remove the needle, check the dose window to confirm the full dose was given, and dispose of the needle safely.

Inject 15mg subcutaneously once per week for 4 weeks (28 days). Rotate injection sites each week and never share your pen.

Needles and alcohol wipes are included in each order but you can purchase more in case of breakage. Mounjaro can be used with any Glucorx Finepoint or GlucoRx Carepoint needles.

• Injection site:
  • It should be injected in the abdomen, thigh or upper arm. The injection site and timing can be changed without dose adjustment.
• Missed dose: If you miss a dose of Mounjaro and,
  • If no more than 4 days have passed since your missed dose, administer it as soon as you recall. Continue with your next injection on the regularly planned day.
  • If it has been over 4 days since the missed dose, omit the missed dose. Proceed with your next injection on the regularly scheduled day.
• Changing day of injection:
  • The day of weekly administration can be changed if necessary, as long as the time between two doses is at least 3 days (>72 hours). After selecting a new dosing day, once-weekly dosing should be continued.
• Storage:
  • Store in a refrigerator (2 °C – 8 °C). Do not freeze. Store in original package to protect from light.
  • Mounjaro may be stored unrefrigerated for up to 21 cumulative days at a temperature not above 30 °C and then the pre-filled pen must be discarded.

• Acute Pancreatitis Concerns with Tirzepatide:
  • Not studied in patients with a history of pancreatitis; caution advised.
  • Reported cases in patients treated with tirzepatide.
  • Discontinue if pancreatitis is suspected; do not restart if confirmed.
• Hypoglycemia Risk in Type 2 Diabetes:
  • Increased risk when combined with insulin secretagogues or insulin.
  • Dose adjustment of insulin or secretagogues may be necessary.
• Severe Gastrointestinal Disease Caution:
  • Use with caution in patients with severe gastrointestinal diseases, including severe gastroparesis.
• Diabetic Retinopathy Caution:
  • Use with caution in patients with diabetic retinopathy; appropriate monitoring is advised.
• Elderly Patients:
  • Very limited data for patients aged ≥85 years, for which is contraindicated.
• Sodium Content:
  • Contains less than 1 mmol sodium (23 mg) per dose, essentially 'sodium-free'.
• Interaction with Other Medicinal Products:
  • Delays gastric emptying, affecting absorption of oral medications.
  • Monitor closely, especially with medications having a narrow therapeutic index.
• Specific Medication Interactions:
  • Oral Contraceptives: Reduction in the blood concentration observed; alternative contraceptive method (barriers) recommended for fertile women starting tirzepatide therapy.
• Pregnancy and Lactation:
  • Limited data on use in pregnant women; not recommended.
  • Unknown if excreted in human milk; weigh benefits against risks.
  • Effect on human fertility unknown; no direct harmful effects in animal studies.
• Effects on Driving and Machine Use:
  • Negligible influence, but precautions are advised when used with sulphonylurea or insulin to avoid hypoglycemia.

• Some side effects may be dose dependent.
• Certain side effects may occur more often in specific patient groups depending on other medicines being taken.
• Fatigue includes both general tiredness and physical weakness.(2) || Skin and Subcutaneous Tissue Disorders | | Hair loss (2) | || General and Injection Site Conditions | Fatigue, injection site reactions (1) | Injection site pain | || Investigations | Heart rate increased (1), lipase increased, amylase increased (1) | Blood calcitonin increased, amylase increased (2), heart rate increased (2) | |

Notes:

• (1) Dose-dependent
• (2) More likely in specific populations
• Fatigue includes both general fatigue and physical weakness